PriceSensitive

Datametrex (TSXV:DM) secures exclusive rights to distribute approved COVID-19 saliva kits

Health Care
TSXV:DM
03 February 2021 09:30 (EDT)
covid 19 testing

Datametrex (DM) secures exclusive rights to sell and distribute FDA, EUA and CE approved COVID-19 saliva kits in Canada and Saudi Arabia.

Datametrex (DM) has secured exclusive rights to sell and distribute COVID-19 saliva kits manufactured by WIZCHEM CO., LTD. in Canada and Saudi Arabia, and non-exclusive rights for the United States of America, United Kingdom, and European Unions.

COVICHEK™ Saliva Kit is a convenient DNA and RNA saliva collection device that stabilizes DNA and RNA long term in saliva sample. The saliva collection tube clearly indicates the volume of saliva required after which the funnel is removed, and cap replaced. The device is fully specified for sample transport and storage.

“Datametrex has been awarded another incredible opportunity to secure an additional medical testing device supplier with WIZCHEM. With the second wave of COVID-19 in the United States and throughout the world, we at Datametrex believe an increase in testing capacity is critical to test, track and protect populations,” said Marshall Gunter, CEO of Datametrex AI Limited.

Since its establishment in 2008, WIZCHEM has been researching, developing, and producing products with global competitiveness to meet customer needs in various fields such as functional chemical materials, biomedical cosmetics, hydrogel wound dressing and medical care. 

Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, Datametrex provides progressive solutions to support the supply chain.

Datametrex AI Limited (DM) is trading at C$0.15 per share as of 9:30 am EST.

Related News